Try our beta test site
3462 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Not yet recruiting Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
Condition: Neuroendocrine Carcinomas
Intervention: Drug: TLC 388
22 Not yet recruiting Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Donafenib
23 Recruiting 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
Condition: Hepatocellular Carcinomas
Intervention: Drug: 188Re-SSS Lipiodol
24 Recruiting Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
Condition: Advanced Lung Squamous Carcinoma
Interventions: Biological: Endostar;   Drug: Docetaxel;   Drug: Cisplatin
25 Recruiting Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma
Condition: Liver Cell Carcinoma Non-resectable
Intervention:
26 Recruiting Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Everolimus , temozolomide
27 Recruiting TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Condition: Hepatocellular Carcinoma
Intervention: Other: Biological: HBV antigen specific TCR redirected T cell
28 Not yet recruiting Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
Condition: Metastatic Renal Cell Carcinoma
Intervention:
29 Recruiting Molecular Determinants for Therapy Response on Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib, Pazopanib, Bevacizumab, Everolimus...
30 Recruiting Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: H3B-6527
31 Recruiting Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Doxorubicin;   Drug: Best Standard of Care
32 Recruiting Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Device: ICESENSE3™
33 Recruiting Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Procedure: Transarterial Chemoembolization;   Radiation: Proton Beam Radiotherapy
34 Not yet recruiting Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Condition: Pulmonary Large Cell Neuroendocrine Carcinoma
Interventions: Drug: etoposide plus carboplatin;   Drug: Paclitaxel plus carboplatin
35 Recruiting Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton Beam Radiotherapy;   Drug: Sorafenib
36 Recruiting Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Radiation: carbon-ion radiotherapy alone;   Radiation: proton plus carbon-ion radiotherapy
37 Recruiting Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Avelumab
38 Recruiting TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Radiation: TheraSphere
39 Recruiting Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)
Condition: Renal Cell Carcinoma
Intervention: Radiation: ARREST-study
40 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.